Sothema Reports 16% Revenue Growth in the First Half of 2026

Moroccan pharmaceutical group Sothema recorded consolidated revenue of MAD 1.79 billion during the first half of 2026, representing an increase of 16%. This performance was supported by business growth and the launch of three new products in Morocco.

The results illustrate the strategic importance of the pharmaceutical industry for the national economy and public health. Developing local production can improve the availability of medicines while reducing dependence on imports.

Sothema’s growth also highlights the potential of Moroccan pharmaceutical companies to innovate, expand their production capacity and strengthen their presence in African and international markets.